Giant Cell Tumor of Bone

Surgical Pathology Clinics

Volumn 5, Issue 1, 2012, Pages 183-200

  Lucas, David R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Anti RANK ligand therapy; Bone remodeling; Cytokine mediated pathways; Giant cell tumor

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOCLAST DIFFERENTIATION FACTOR INHIBITOR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

BONE CANCER; BONE RADIOGRAPHY; CLINICAL FEATURE; GIANT CELL TUMOR; HISTOPATHOLOGY; HUMAN; INOPERABLE CANCER; METASTASIS; MOLECULAR BIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 84856640142     PISSN: 18759181     EISSN: 18759157     Source Type: Journal    
DOI: 10.1016/j.path.2011.07.012     Document Type: Review

References (16)

1. Thomas D., Henshaw R., Skubitz K., et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010, 11(3):275-280.
2. Nishimura M., Yuasa K., Mori K., et al. Cytological properties of stromal cells derived from giant cell tumor of bone (GCTSC) which can induce osteoclast formation of human blood monocytes without cell to cell contact. JOrthop Res 2005, 23(5):979-987.
3. Murata A., Fujita T., Kawahara N., et al. Osteoblast lineage properties in giant cell tumors of bone. JOrthop Sci 2005, 10(6):581-588.
4. Ghert M., Simunovic N., Cowan R.W., et al. Properties of the stromal cell in giant cell tumor of bone. Clin Orthop Relat Res 2007, 459:8-13.
5. Morgan T., Atkins G.J., Trivett M.K., et al. Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappa B. Am J Pathol 2005, 167(1):117-128.
6. Atkins G.J., Kostakis P., Vincent C., et al. RANK Expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. JBone Miner Res 2006, 21(9):1339-1349.
7. Fechner R.E., Mills S.E., Armed Forces Institute of Pathology (U.S.), Universities Associated for Research and Education in Pathology Tumors of the bones and joints 1993, Armed Forces Institute of Pathology: Available from the American Registry of Pathology Armed Forces Institute of Pathology, Washington, DC.
8. Unni K.K., Inwards C.Y., Bridge J.A., et al. Tumors of the bone and joints 2005, vol. 4. American registry of pathology, Silver Spring (MD).
9. Oliveira A.M., Dei Tos A.P., Fletcher C.D., et al. Primary giant cell tumor of soft tissues: a study of 22 cases. Am J Surg Pathol 2000, 24(2):248-256.
10. Fain J.S., Unni K.K., Beabout J.W., et al. Nonepiphyseal giant cell tumor of the long bones. Clinical, radiologic, and pathologic study. Cancer 1993, 71(11):3514-3519.
11. Bridge J.A., Neff J.R., Bhatia P.S., et al. Cytogenetic findings and biologic behavior of giant cell tumors of bone. Cancer 1990, 65(12):2697-2703.
12. Schwartz H.S., Juliao S.F., Sciadini M.F., et al. Telomerase activity and oncogenesis in giant cell tumor of bone. Cancer 1995, 75(5):1094-1099.
13. Si A.I., Huang L., Xu J., et al. Expression and localization of extracellular matrix metalloproteinase inducer in giant cell tumor of bone. JCell Biochem 2003, 89(6):1154-1163.
14. Dahlin D.C., Cupps R.E., Johnson E.W. Giant-cell tumor: a study of 195 cases. Cancer 1970, 25(5):1061-1070.
15. Rock M.G., Pritchard D.J., Unni K.K. Metastases from histologically benign giant-cell tumor of bone. JBone Joint Surg Am 1984, 66(2):269-274.
16. Kay R.M., Eckardt J.J., Seeger L.L., et al. Pulmonary metastasis of benign giant cell tumor of bone. Six histologically confirmed cases, including one of spontaneous regression. Clin Orthop Relat Res 1994, (302):219-230.